About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals is a company based in Watertown (United States) founded in 2006 was acquired by La Jolla Pharmaceutical in June 2020.. Tetraphase Pharmaceuticals has raised $80.04 million across 5 funding rounds from investors including La Jolla Pharmaceutical, Flagship Pioneering and Excel Venture Management. The company has 31 employees as of December 31, 2020. Tetraphase Pharmaceuticals operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Watertown, United States
- Employees 31 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$80.04 M (USD)
in 5 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Jan 28, 2020
-
Investors
La Jolla Pharmaceutical
& 7 more
-
Employee Count
31
as on Dec 31, 2020
-
Acquired by
La Jolla Pharmaceutical
(Jun 24, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals has successfully raised a total of $80.04M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $10.0M
-
First Round
First Round
(01 Nov 2006)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Post-IPO - Tetraphase Pharmaceuticals | Valuation |
investors |
|
| May, 2010 | Amount | Series C - Tetraphase Pharmaceuticals | Valuation | Excel Medical Ventures | |
| Sep, 2009 | Amount | Series B - Tetraphase Pharmaceuticals | Valuation | F-Prime Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include La Jolla Pharmaceutical, Flagship Pioneering and Excel Venture Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
US life sciences companies are invested in by Skyline Ventures.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Tetraphase Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Tetraphase Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tetraphase Pharmaceuticals Comparisons
Competitors of Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| domain | founded_year | HQ Location |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| domain | founded_year | HQ Location |
Developer of antibiotics for MDR infections
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| domain | founded_year | HQ Location |
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tetraphase Pharmaceuticals
Frequently Asked Questions about Tetraphase Pharmaceuticals
When was Tetraphase Pharmaceuticals founded?
Tetraphase Pharmaceuticals was founded in 2006.
Where is Tetraphase Pharmaceuticals located?
Tetraphase Pharmaceuticals is headquartered in Watertown, United States.
Is Tetraphase Pharmaceuticals a funded company?
Tetraphase Pharmaceuticals is a funded company, having raised a total of $80.04M across 5 funding rounds to date. The company's 1st funding round was a Series B of $10M, raised on Nov 01, 2006.
How many employees does Tetraphase Pharmaceuticals have?
As of Dec 31, 2020, the latest employee count at Tetraphase Pharmaceuticals is 31.
What does Tetraphase Pharmaceuticals do?
Tetraphase Pharmaceuticals was founded in 2006 as a clinical-stage biopharmaceutical company based in Watertown, United States. Proprietary chemistry technology is employed to produce novel tetracycline analogs targeting multidrug-resistant infections. A library exceeding 2500 compounds has been assembled and is screened against bacterial targets. The lead candidate, Eravacycline, a fully synthetic fluorocycline antibiotic, is advanced in phase 3 trials for complicated intra-abdominal infections and complicated urinary tract infections.
Who are the top competitors of Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Who are Tetraphase Pharmaceuticals's investors?
Tetraphase Pharmaceuticals has 8 investors. Key investors include La Jolla Pharmaceutical, Flagship Pioneering, Excel Venture Management, CMEA Capital, and Mediphase Venture Partners.